WAVE Life Sciences (WVE) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 5, 2021 7:30 AM EDTDosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD first oligonucleotide using PN backbone chemistry modifications in clinical study
Recruitment ongoing for clinical trials in HD and DMD
Generating clinical data in multiple trials through 2022 to enable decision making
Leading endogenous ADAR editing capability demonstrated restoration of functional AAT protein in vivo; new data at Wave Research Day September 28
Wave to host investor conference call and webcast at 8:30 a.m. ET today
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq:... More
